EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Condition:   Colo-rectal Cancer Interventions:   Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Drug: Irinotecan;   Biological: Cetuximab;   Procedure: Metastasectomy;   Procedure: Biospecimen collection Sponsor:   Roswell Park Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials